NEW YORK — Having launched a digital screening test for preterm birth in November, diagnostics firm Nixxi is preparing this quarter to release a mass spectrometry-based test for predicting preterm birth and infant morbidity.
The company is currently working out a partnership with a CLIA lab and completing a validation study that to support the launch of the test, said Avi Patil, founder and CEO of the Phoeniz, Arizona-based firm.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
